ARTICLES BY ERIC LANGER

• Cell And Gene Therapy Bioprocessing: Hiring And Capacity Crunch On The Horizon

  5/21/2020

  With a very healthy R&D pipeline of cell and gene therapies, we can expect multiple blockbuster products and various “orphan” niche products to be launched annually in coming years. As a result, the industry is heading for a capacity crunch.

• A Biopharma Year In Review — And A Look Ahead To 2020

  12/16/2019

  The industry has shown surprising resilience and consistency, emerging relatively unscathed from the recession at the beginning of the past decade. Capacity and expansion were relatively unaffected and continue to draw investors seeking healthy returns and a recession-resistant risk profile.

• Bioprocessing Trends To Watch In 2018

  12/6/2017

  The current situation in biopharma is exciting, with new technologies, biosimilars, cellular and gene therapies, and opportunities in emerging markets.  And these innovative platforms are going to continue to need improved manufacturing technologies in the future.

• Biosimilars Paving The Way For Cost-Effective Bioprocessing

  8/23/2017

  As biosimilars finally move into mainstream commerce in the world’s major (bio)pharmaceutical markets, they are bringing with them some side benefits. Sponsors frequently focus resources on production technologies that generate higher productivity and yields. Some of these cutting-edge technologies are applicable to mainstream pipeline biologics, so future biopharmaceuticals will benefit from this push for efficiency.

• 2017 Biopharmaceutical Trends — Opportunities For The New Year

  12/20/2016

  Although change is constant, it generally comes very slowly to the highly regulated biopharma industry. Bringing a biologic to market can be a decades-long process, so tracking trends needs to take a long view. Based on decades of analysis, and findings from our 13th Annual Report of Biopharmaceutical Manufacturing, this article will outline some of the key factors affecting the industry today.

• Continuous Bioprocessing Overtakes Single-Use On List Of Top Technology Trends

  10/10/2016

  The desire for innovation in the biopharmaceutical manufacturing industry continues unabated, as companies ramp up their spending on new technologies to improve efficiencies in both upstream and downstream bioprocessing. And while innovation in this industry can be slow to come, the past decade has seen the emergence of several new innovative trends, ranging from the proliferation of single-use devices to growing demand for continuous bioprocessing and modular facilities, according to BioPlan Associates’ 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.

• 4 Key Trends In Biopharmaceutical Manufacturing In 2016

  3/16/2016

  One of the most important trends to emerge from preliminary results of this year’s survey is the increased attention paid to continuous bioprocessing. Integrated, broad up- and downstream technologies remain to be developed and commercialized. Despite this lack of viable options, there is a groundswell of enthusiasm for the concept.

• Single-Use Standardization: Is It Holding Back The Biopharma Industry?

  6/1/2015

  The data from BioPlan Associates’ 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production speaks to the industry’s ongoing desires for standardization in single-use devices. As usage of these disposable devices increases, the gap between the importance of standardization and end-users’ satisfaction with their supplier’s standardization efforts has steadily been worsening. 

• New Single-Use Devices: Trends And Demands
  Single-Use Biomanufacturing Devices In High Demand

  1/5/2012

  Single-use devices are in hot demand as the biopharma industry looks for new, more innovative products. In fact, disposables make up the top 3 of 20 areas of new product development interest this year. By Eric Langer, president and managing partner, BioPlan Associates, Inc.